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Background: Zuo-Jin-Wan (ZJW), a traditional Chinese medicine formula, has been identified to be effective against
drug resistance in cancer. In the present study, we investigated the effect of ZJW on acquired oxaliplatin-resistant
and the PI3K/Akt/NF-κB pathway in vitro.
Methods: We tested the dose–response relationship of ZJW on reversing drug-resistance by CCK-8 assay and flow
cytometry analysis in vitro. The protein expression of P-gp, MRP-2, LRP, and ABCB1 mRNA expression level were
evaluated by Western blot and quantitative RT-PCR. The activities of PI3K/Akt/NF-κB pathway were also examined
with or without ZJW, including Akt, IκB, p65 and their phosphorylation expression.
Results: We found that ZJW significantly enhanced the sensitivity of chemotherapeutic drugs and increased oxaliplatin
(L-OHP)-induced cell apoptosis in a time- and dose-dependent manner. Moreover, both ZJW and a PI3K specific
inhibitor (LY294002) suppressed phosphorylation of Akt (Ser473) and NF-κB, which is necessary in the activation
of the PI3K/Akt/NF-κB pathway. The effect of ZJW in reversing drug-resistance and suppressing phosphorylation
of Akt (Ser473) and NF-κB were weakened after treatment with a PI3K/Akt activator in HCT116/L-OHP cells.
Conclusions: Our study has provided the first direct evidence that ZJW reverses drug-resistance in human colorectal
cancer by blocking the PI3K/Akt/NF-κB signaling pathway, and could be considered as a useful drug for cancer therapy.
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Colorectal cancer (CRC) is the second commonest cause
of cancer-related deaths in the Western World, and re-
sistance to chemotherapy remains the primary reason
for treatment failure in advanced CRC [1]. Chemother-
apy is an important therapeutic method for CRC pa-
tients. However, the development of drug resistance
usually results in the failure of chemotherapy [2]. Drug-
resistance of a tumor can be divided into targeting re-
sistance, which arises to one or two special drugs, and
multidrug resistance (MDR), which means the resistance
of cancer cells to one chemotherapeutic drug accompanied* Correspondence: Lzwf@hotmail.com
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unless otherwise stated.by resistance to other chemotherapeutic drugs that may
have different structures and mechanisms of action [3].
To date, the most important potential mechanism of
drug-resistance is the ABC transporter family, including
the well known P-glycoprotein (P-gp, encoded by the
ABCB1 gene), MDR-associated protein 1 (MRP1, encoded
by the ABCC1 gene) and ABC subfamily G member 2 [4].
To reverse cellular transport protein-mediated drug-
resistance, studies have been conducted to explore pos-
sible mechanisms via signaling pathways, including
phosphatidylinositol 3-kinase (PI3K) signal transduction.
The phosphoinositide 3-kinases (PI3Ks), a family of
lipid kinases that propagate intracellular signaling
cascades regulating a wide range of cellular processes,
are believed to be one of the reasons for the develop-
ment of chemoresistance during cancer therapy [5].
PIP3, which is a PI3K phosphorylation product, brings. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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phosphoinositide-dependent kinase 1 (PDK1), and AKT
into close proximity [6]. Previous studies have also in-
dicated that Akt phosphorylation can induce drug-
resistance in several kinds of tumors, such as ovarian
cancer [7], breast cancer [8], and hepatocellular carcin-
omas [9]. Furthermore, AKT impedes negative regulation
of the transcription factor NF-κB, leading to increased
transcription of antiapoptotic and prosurvival genes [10].
In fact, spontaneous activation of NF-κB has been de-
tected in human colorectal cancer tissues, and activation
of NF-κB is believed to result in the chemoresistant
phenotype in colorectal cancer cells [4,11].
Zou-Jin-Wan (ZJW), a traditional Chinese medicine for-
mula, has been used as a therapy to slow colorectal cancer
progression, improve quality of life, and prolong survival
times. ZJW is composed of Rhizoma Coptidis and Fructus
Evodiae in the ratio 6:1 (w/w). Coptis chinensis Franch,
the main component of Rhizoma Coptidis, has been re-
ported to reverse drug-resistance cancer [12,13] and sup-
press the nuclear translocation of p50/p65 NF-κB proteins
and their binding to target genes [14]. Fructus Evodiae
and its major alkaloid component, evodiamine, have been
demonstrated to induce apoptosis in human melanoma
A375-S2 cells, lead to inactivation of the PI3K/Akt/NF-κB
pathway, and stop the translocation of NF-κB [15].
Although the role of Rhizoma Coptidis and Fructus
Evodiae in the PI3K/Akt/NF-κB pathway have been
investigated extensively, much less is known about
their potential role in regulating drug-resistance when
mixed in ZJW.
Although the ZJW herbal formula has anti-cancer effects,
its underlying mechanism in reversing drug-resistance re-
mains unknown. In this study, we aimed to elucidate the ef-
fect and the molecular mechanisms of the Chinese herbal
formula, ZJW, in human cancer cells in vitro.
Methods
Preparation of the extracts for ZJW
Rhizoma Coptidis and Evodia were purchased from
Lei-Yun-Shang Pharmaceutical Group (Shanghai) and
identified as the coptis of ranunculaceae and the fruit
of Tetradium, respectively. They were formally identi-
fied by Professor DZ Wu (The School of Pharmacy,
Shanghai University of Traditional Chinese Medicine,
Shanghai, China).
ZJW was formulated by Rhizoma Coptidis and Evodia
(in a ratio of 6:1). All the herbs were purchased from
ShuGuang Hospital herb store and were done as de-
scribed previously [1]. Briefly, the mixture (70 g) was ex-
tracted twice for 1 h each time by refluxing in ethanol
(1:8, v/v). The filtrates were concentrated and dried in
vacuum at 60°C. The concentrated extract was then
dried by lyophilization to obtain the ZJW extract at ayield of dried powder of 24.4%. The extract was stored
at 4°C, and its preparations were standardized, regulated
and quality controlled according to the guidelines de-
fined by Chinese State Food and Drug Administration
(SFDA).
Cell culture and reagents
Human colorectal cancer HCT116 cells were purchased
from the Shanghai Cell Collection (Shanghai, China).
The HCT116/L-OHP MDR cell lines were established
and maintained in our laboratory. Cells were grown in
RPMI 1640 medium supplemented with 10% (v/v) heat-
inactivated fetal calf serum, 2 mM glutamine, 100 units/
mL penicillin, and 100 μg/mL streptomycin (Invitrogen,
Carlsbad, CA) at 37°C in a 5% CO2 humidified atmos-
phere. HCT116/L-OHP cells were routinely maintained in
a medium containing 5,000 ng/mL oxaliplatin (L-OHP).
Monoclonal antibodies against P-gp, MRP-2, LRP, IκB,
Akt, p65, and GAPDH were purchased from Cell Signaling
Technology (Beverly, MA, USA).
Cell viability assays
Cell proliferation was determined using the cell counting
kit, CCK-8. Briefly, cells were seeded in 96-well plates at
1 × 104 cells/well. When the cells reached 60% conflu-
ence, the medium was removed and replaced with fresh
medium containing varying concentrations of ZJW or its
mixture with anti-tumor drug (L-OHP) and incubated
for 48 h. The CCK-8 assay was then performed: after 2 h
of incubation with culture medium containing the CCK-
8 reagent, the absorbance was read at 450 nm using a
microplate assay reader (Labsystems Dragon, Wellscan).
Relative inhibitory rate of cell growth was calculated
according to the formula: R = (A2 − A1)/A2 × 100% and
P = A1/A2 × 100%, in which R was relative inhibitory
rate, P was relative proliferation ratio of cell growth,
A1 is the mean absorbance of transfected cells, and A2
is the mean absorbance value of untransfected control
cells without drug treatment. All experiments were
done with five wells per experiment in triplicate.
Apoptosis and cell-cycle assay
Cells were seeded in 6-well plates (4 × 105 cells/well).
After 12 h, three dose concentrations of ZJW were
added. Flow cytometry was used to detect apoptosis by
determining the relative amount of AnnexinV-FITC-
positive-PI-negative cells, as previously described [1].
Unstained cells, cells stained with Annexin V-FITC
alone, and cells stained with propidium iodide alone
were used as controls. Singly stained cells were used to
adjust electronic compensation on the FL1 and FL2
channels. After apoptosis assay, cell cycle distributions
were analyzed with the ModFit program (BD, San Diego,
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the fraction of each cell cycle phase was calculated.
Western blot analysis
Whole cell lysate for SDS-PAGE and western blot ana-
lysis for P-gp, MRP-2, LRP, IκB, Akt, p65, and phosphor-
ylation of Akt and IκB expression was prepared as
previously reported [1]. The lysate was incubated on ice
in immunoprecipitation assay buffer for 2 h before being
homogenized using a mortar and pestle. The homoge-
nized sample was centrifuged, and the supernatant was
collected and stored at −80°C. Equal loading was con-
firmed with GAPDH. Densitometric analysis was done
using the Scion Imaging software (Scion Corporation),
with GAPDH as internal control.
Quantitative RT-PCR analysis
Tumor cells were homogenized and suspended with an
RNAspin Mini Kit (GE Healthcare, Waukesha, WI, USA)
for RNA isolation according to the manufacturer’s instruc-
tion. For cDNA synthesis, 1 μg of total RNA was reverse-
transcribed using oligo-dT primers and the Superscript
Amplification System (Life Technologies, Carlsbad, CA,
USA). Quantitative RT-PCR was carried out using SYBR
Green PCR Master Mix (Life Technologies). The PCR pa-
rameters consisted of initial polymerase activation at 94°C
for 5 min, followed as previously described [1]. Amplifica-
tion of GAPDH RNA, a relatively invariant internal refer-
ence was performed in parallel, and cDNA amounts were
normalized to equivalent GAPDH mRNA levels. Oligo-
nucleotide primers for ABCB1 and GAPDH were as
follows: Oligonucleotide sequence of ABCB1 (379 bp),
F: 5′-TAATGCGACAGGAGATAGG-3′, R: 5′-TGCCAT
TGACTGAAAGAAC-3′, Oligonucleotide sequence of
GAPDH (306 bp), F: 5′-ACCCACTCCTCCACCTTTGA-3′,
R: 5′-CTGTTGCTGTAGCCAAATTCGT-3′.
ABCB1 promoter activity by vector transient transfection
and dual luciferase assay
Transfection procedures were performed according to
manufacturers’ instructions, with Lipofectamin 2000 as
transfection reagent (Invitrogen). Briefly, 2 × 103 cells
were plated in each well of a 96-well plate and incubated
overnight. A mixture of Lipofectamine 2000 (10 nM)
with ABCB1 promoter recombinant vector pGL3-Basic-
ABCB1 promoter (0.8 μg/well) was added, followed by a
48 h incubation in regular medium. Then cells were har-
vested and analyzed using a dual-luciferase assay kit
(Shanghai Lai’an Biotech. Co., Ltd, Shanghai, China) as
previously reported [1].
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was done as de-
scribed previously [16]. N-ethylmaleimide was added tothe cell lysis buffer at a final concentration of 10 mM to
preserve poly-ubiquitinated protein conjugates.
Statistical analysis
All experimental data are expressed as mean ± standard
deviation of at least three independent experiments per-
formed in duplicate. Significance was determined by a
one-way analysis of variance (ANOVA) and Holm’s
multiple-comparison test. Statistical significance was set
at a P-value of less than 0.05. All analyses were carried
out using SPSS13.0 (SPSS, Chicago, IL, USA).
Results
ZJW modulates L-OHP resistance in vitro
We previously showed that ZJW enhances the inhibition
rate of chemotherapeutic agents in a dose-dependent man-
ner in MDR tumor cells, including colorectal cancer cells
(HCT116/L-OHP), gastric carcinoma cells (SGC7901/
DDP), and hepatic carcinoma cells (Bel/Fu). To further
examine the effect of ZJW in reversing chemoresis-
tance, we detected the cell proliferation in response to
chemotherapeutic agents by the CCK-8 assay and
apoptosis by flow cytometry. As shown in Figure 1A,
ZJW caused a significant decrease in the cell inhibition
rate of chemotherapeutic agents in a time-dependent
manner. However, sensitive cell proliferation treatment
with ZJW and L-OHP were not found to be signifi-
cantly different from L-OHP control group (Figure 1B).
Similar to our previous study, ZJW increased L-OHP-
induced cell apoptosis in a dose-dependent manner
(Figure 1C). To further examine the effect of ZJW in
cell cycle, Flow cytometric analysis was used after
HCT116/L-OHP cells in response to ZJW only without
HCT116/L-OHP. However, the cell cycle analyses data
showed that there was no change in any phase arrest,
especially in sub-G0 population of cell (Figure 1D),
suggesting that ZJW did not alter cell cycle in HCT-
116/L-OHP cells. Therefore, these data suggest that
ZJW is responsible for reversing chemoresistance in its
lowest dosage of the IC10 with a time- and dose-
dependent manner.
The effect of ZJW and PI3K/Akt pathway on L-OHP
resistance
Previous studies have demonstrated that the PI3K/Akt
pathway is activated in various tumor MDR cell types.
To ascertain whether the reversal of drug-resistance by
ZJW in colorectal cancer cells is correlated with the acti-
vation of the PI3K/Akt pathway, a PI3K specific inhibi-
tor (LY294002) and activator (IGF-1) were added to
HCT116/L-OHP cells as described. As expected, pre-
treatment with LY294002 or ZJW increased the sensitiv-
ity to chemotherapy and allowed the chemotherapeutic
drugs to induce cell apoptosis (Figure 2A and B). However,
ZJW(0 g/mL) ZJW(12.5 g/mL)
ZJW(25 g/mL) ZJW(50 g/mL) 
Channels (FL2-A)































Figure 1 ZJW modulates the MDR phenotype in a dose- and time-dependent manner. (A&B) CCK-8 assay was used to detect the cellular
inhibition of L-OHP in HCT116 cells and HCT116/L-OHP cells treated with ZJW at 50 μg/mL for 24, 48, and 72 h. (C) Flow cytometry analysis of
apoptosis with Annexin V-FITC/PI binding to HCT116/L-OHP cells after treatment with ZJW at 0, 12.5, 25, and 50 μg/mL for 48 h. (D) Flow
cytometry analysis was used to distinguish cells in different phases of the cell cycle as Methods described.
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L-OHP resistance as compared with the ZJW or LY294002
groups (Figure 2A and B).
ZJW inhibits P-gp expression and the effect of the PI3K/Akt
pathway
To further investigate the mechanisms underlying the ef-
fect of ZJW and its relationship with the PI3K/Akt path-
way, three cell membrane-bound ATP binding cassette
(ABC) transporters, P-gp, MRP-2, and LRP, were deter-
mined by western blot. Previous study revealed thatZJW administration to MDR cells was accompanied with
the downregulation of P-gp, but not other proteins [1]. As
shown in Figure 3A and B, LY294002 decreased the expres-
sion of P-gp significantly. Moreover, P-gp expression was
up-regulated when cells were treated with ZJW and IGF-1.
Similarly, we observed a down-regulation in the expression
of ABCB1 mRNA in a dose-dependent manner when
HCT116/L-OHP cells were treated with ZJW (Figure 3C).
These findings support the hypothesis that inhibition of P-
gp by ZJW is attributable to suppression of the translational




Figure 2 ZJW reversed constitutive as well as PI3K/Akt pathway-induced MDR phenotype. (A) Anti-proliferative IC50 values of L-OHP on
HCT116/L-OHP cell treated with LY294002 (20 μM, 2 h), ZJW (50 μg/mL, 48 h), and a combination of ZJW (50 μg/mL, 48 h) and IGF-1 (100 ng/mL,
48 h), were analyzed by CCK-8. Data are presented as mean ± SD of triplicate experiments. **P < 0.01 vs. control, #P < 0.05 vs. ZJW group. (B) Flow
cytometry analysis of apoptosis with Annexin V-FITC/PI binding to HCT116/L-OHP cells treated with LY294002 (20 μM, 2 h), ZJW (50 μg/mL, 48 h),
and a combination of ZJW (50 μg/mL, 48 h) and IGF-1 (100 ng/mL, 48 h).
Figure 3 ZJW inhibits P-gp expression and the effect of the PI3K/Akt pathway. (A) Western blotting assay was carried out to detect the
level of P-gp, LRP, and MRP-2 in HCT116/L-OHP cells treated with LY294002 (20 μM, 2 h), ZJW (50 μg/mL, 48 h), and a combination of ZJW
(50 μg/mL, 48 h) and IGF-1 (100 ng/mL, 48 h). GAPDH was used to ensure equal loading of proteins in each lane. (B) Blots were photographed
and quantitated; the data are from three independent experiments. (C) Real-time PCR was performed to detect ABCB1 mRNA in vivo. Quantification
of ABCB1 mRNA was performed by assigning a value of 1 to the control group treatment with ZJW (50 μg/mL). Statistical difference was analyzed by
student’s t-test, **P < 0.01 vs. control group; #P < 0.05 vs. ZJW (50 μg/mL) group. This is a representative result of three experiments with similar results.
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activation of the PI3K/Akt/NF-κB pathway in vitro
To determine whether the PI3K/Akt pathways are in-
volved in the P-gp mediated drug-resistance phenotype
in colorectal cancer, the expression of Akt and Akt phos-
phorylation (Thr307 and Ser473) were examined in
HCT116/L-OHP cells by western blotting. Notably, ZJW
or LY294002 decreased the expression of Akt phosphor-
ylation (Ser473) in HCT116/L-OHP cells (Figure 4A),
but did not significantly affect the expression of Akt or
p-Akt at Thr307. Additionally, this inhibition was weak-
ened after the addition IGF-1 (Figure 4A). These obser-
vations suggest that PI3K/Akt pathway activation could
regulate the expression of P-gp, which is involved in
controlling the drug-resistance phenotype.Figure 4 ZJW suppresses P-gp mediated MDR by inhibiting activa
(A&B) Western blotting assay was carried out to detect the level of Akt, ph
in HCT116/L-OHP cells treated with LY294002 (20 μM, 2 h), ZJW (50 μg/mL, 4
48 h). GAPDH was used to ensure equal loading of proteins in each lane. Dat
control group.Evidence suggests that the PI3K/Akt pathway is in-
volved in the development of chemoresistance, at least
in part by the activation of NF-κB. In light of our results,
we examined the effect of ZJW on NF-κB and phosphor-
ylation of NF-κB in the cytoplasm and p65 levels in the
nucleus. Similar to the effect on Akt and p-Akt, we ob-
served a down-regulation of NF-κB phosphorylation in
HCT116/L-OHP cells treated with ZJW or LY294002
(Figure 4B).
Since the ABCB1 promoter is shown to bind with NF-
κB, we hypothesized that there would be a down-regulation
of ABCB1 promoter activity after treatment with ZJW. We
found that the activity of the ABCB1 promoter was down-
regulated after cells were treated with ZJW (Figure 5D). To
further ascertain whether NF-κB protein could bind to thetion of Akt (Ser473)/IκB phosphorylation (Ser473) in vitro.
osphorylation of Akt (Thr307/Ser473), IκB, p65, and phosphorylation of IκB
8 h), and a combination of ZJW (50 μg/mL, 48 h) and IGF-1 (100 ng/mL,
a are means ± SD of values from triplicate experiments. **P < 0.01 vs.
Figure 5 ZJW suppresses P-gp mediated MDR by inhibiting activation of NF-κB pathway in vitro. (A) ChIP analysis between NF-κB protein
and ABCB1 gene. As a control, mouse monoclonal IgG was used. The blank group was the PCR results with no cDNA, and the input group was
the cDNA from cell lysates without RIP procedure. (B) ChIP analysis was carried out to detect the effect of ABCB1 gene in HCT116/L-OHP cells
treated with ZJW (50 μg/mL, 48 h). As a control, mouse monoclonal IgG was used. Input group was the cDNA from cell lysates without RIP procedure,
and anti-NF-κB group was the cDNA from cell lysates after treatment with NF-κB antibody. (C) Western blotting assay was carried out to detect the level
of P-gp, p-Akt (Ser473), p-IκB and p65 between HCT116 cell and HCT116/L-OHP cell. (D) The activity of the ABCB1 promoter in HCT116/L-OHP cells
treated with LY294002 (20 μM, 2 h), ZJW (50 μg/mL, 48 h), and a combination of ZJW (50 μg/mL, 48 h) and IGF-1 (100 ng/mL, 48 h), was analyzed by a
dual-luciferase assay kit. The results are the firefly luciferase/renilla luciferase ratio from different groups. Data are means ± standard deviation of values
from triplicate experiments. **P< 0.01 vs. control group.
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and ABCB1 by ChIP. ChIP assay confirmed that the NF-κB
protein could bind to the ABCB1 gene promoter in
HCT116/L-OHP cells, but not in HCT116 cells (Figure 5A).
As presupposed, it indeed a down-regulation of ABCB1
mRNA expression after treatment with ZJW compared
with control group (Figure 5B). Similar as the results in
Figure 5A, the level of P-gp, p-Akt (Ser473), p-IκB andp65 were significantly increased in HCT116/L-OHP cell
compared with HCT116 cell (Figure 5C). It indicated the
difference between MDR cell and sensitive cell, which may
be an important mechanism of drug-resistance phenotype.
Therefore, ZJW was identified as a PI3K/Akt/NF-κB path-
way inhibitor, which inhibits the phosphorylation of Akt
and NF-κB and the binding of NF-κB and ABCB1 in MDR
cell nuclei.
Sui et al. BMC Complementary and Alternative Medicine 2014, 14:279 Page 8 of 10
http://www.biomedcentral.com/1472-6882/14/279Discussion
The aim of this study was to investigate whether the
anti-drug-resistance effect of ZJW was via inhibition of
PI3K/Akt/NF-κB signaling in colorectal drug-resistance
cancer. Our previous studies demonstrated that ZJW
could reverse the MDR phenotype by increasing the sen-
sitivity of MDR cells to chemotherapeutic agents and
inhibiting P-gp expression both in vitro and in vivo [1].
In the present study, we investigated the anti-cancer mo-
lecular mechanisms of ZJW ethanol extracts in signal
pathways reversing drug-resistance.
In colorectal cancer, patients who do not respond to
chemotherapy usually have a high expression of various
ABC transporter pumps, which are located on the cyto-
plasmic side of the resistant cell membrane, resulting in
an increased drug efflux [17]. In addition, the effective-
ness of current chemotherapeutic agents is limited by
drug resistance, thus the discovery of the mechanisms
governing the cellular response to chemotherapy and de-
velops a new strategy for treatments are priority [18].
Traditional Chinese prescriptions and formulae can be
used as a therapy to effectively control cancer progres-
sion, improve quality of life, and prolong survival times
instead of conventional chemotherapy [19-21].Figure 6 Schematic summary of the inhibition mechanisms of ZJW on
pathway could reduce MDR phenotype. ZJW suppress phosphorylation of AktSeveral studies have demonstrated that the PI3K/AKT
pathway activates the NF-kB system, which could lead to
increase the transcription of target genes such as ABCB1
[22], COX-2 [23], and p53 [24]. Therefore, a definitive
relationship between the PI3K/AKT/NF-kB pathway and
drug-resistance has yet to be established [25]. However,
no report has examined the effect any drug on the reversal
of drug-resistance via blockage of the PI3K/Akt/NF-kB
signal pathway in colorectal cancer.
ZJW, a traditional Chinese herbal medicine, is viable
and effective for inhibiting drug-resistance in lowest dos-
age of the IC10 to MDR cells [1]. In the present study,
the concentration range of 50 μg/mL (IC10 to ZJW) was
also used to help enhance the sensitivity of chemothera-
peutic agents in the cell proliferation, apoptotic, but not
in cell cycle. However, the mechanism of ZJW in the re-
sistance to MDR cancer remains unknown. Earlier re-
ports showed that evodiamine, a component of ZJW,
could inhibit the PI3K/Akt pathway and targeted NF-κB
in pancreatic cancer [26]. In our study, a remarkable ac-
tivation of phosphorylation AKT and NF-κB was de-
tected in HCT116/L-OHP cells, which also have up-
regulation of P-gp. In addition, we showed that the levels
of phosphorylation AKT and NF-κB in HCT116/L-OHPthe PI3K/Akt/NF-κB signaling pathway. Activation of PI3K/Akt/NF-κB
(Ser473) and NF-κB.
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fects of ZJW in inhibiting of the level of P-gp, phosphor-
ylation AKT, and NF-κB were weakened after treatment
with the PI3K/Akt activator in HCT116/L-OHP cells.
Therefore it is reasonable to believe that ZJW might play
a suppressive role in the expression of P-gp via inhib-
ition of the PI3K/Akt/NF-κB pathway.
These results are consistent with previous reports and
may explain the effects of ZJW, including enhancing the
inhibition rate of chemotherapeutic agents in a time-
dependent manner, and helping chemotherapeutic drugs
induce cell apoptosis in a dose-dependent manner.
These results also agree with in vivo data that showed
that ZJW was able to reduce tumor volume and induce
cell apoptosis with the combination of chemotherapeutic
agents [27]. Therefore, ZJW exhibits down-regulation of
the expression of ABCB1/P-gp via inhibition of the
PI3K/Akt/NF-κB pathway in vitro.
Conclusions
In conclusion, based on our previous clinical and experi-
mental studies, ZJW can be used as an inhibitor of che-
moresistance in CRC. The present investigation has
shown that the anti-MDR activity of ZJW can be par-
tially attributed to the inhibition of the PI3K/Akt/NF-κB
pathway and can modulate the binding of the ABCB1
promoter (Figure 6). Therefore, this study has provided
a natural potent inhibitor of drug-resistance in human
cancer. Compared with modern medicine, the combin-
ation of multiple herbs may yield better results in cancer
treatment. The development of treatment with ZJW will
be explored as a potential therapeutic strategy in human
drug-resistance cancer.
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